The recall of the StealthStation S8 application due to a serious software error is likely to negatively impact Medtronic's stock in the short term. The FDA's classification of the recall as Class I, the most serious kind, underscores the severity of the issue. Although Medtronic plans to offer a software update to resolve the error, the immediate negative sentiment and potential impact on the company's reputation and sales are likely to drive the stock price down.